CBS and ovarian carcinoma: Precise drug delivery by dendrimer nanoparticles is easily achieved by surface targeting, and folate-targeted dendrimers in particular are a relevant choice in cancer therapeutics, because cancer cells overexpress the folate receptor.242 Mota et al.243 developed folate-targeted dendrimers that are able to load and release L-BSO, whereas Santos et al.244 also used nanoparticles to produce selenium-chrysin (SeChry) nanoformulations to target glutathione bioavailability and CBS, aiming at novel ovarian cancer therapeutics (Fig. 5d).